

## About the Merlin™ Test:

Jointly developed by SkylineDx and Mayo Clinic, the Merlin™ gene expression profiling test has been validated in multicenter clinical trials in the U.S. and EU. The Merlin test utilizes a genomic-based algorithm to help identify newly diagnosed cutaneous melanoma patients at high risk of nodal metastasis from those at low risk. Patients at low risk may forgo sentinel lymph node biopsy (SLNB), while patients at higher risk may benefit from SLNB surgery.

The Merlin test is the first test to combine clinicopathological variables with gene expression profiling (CP-GEP) that can inform if a melanoma patient may or may not forgo a SLNB. Unlike similar gene-expression tests, the Merlin™ test is the only CP-GEP-based test that provides a binary, actionable result.

The Merlin test has been commercially available in the US since 2022 and is performed in our CAP/CLIA accredited clinical laboratory located in San Diego, CA.

## Patient Selection:

- SLNB eligible patients
- pT1a (with adverse features)
- pT1b-pT3

## Clinical Publications:

Since Mayo Clinic first released their study in 2015, the Merlin test has been the subject of almost a dozen peer-reviewed studies in the US and the EU.

These studies can be accessed on our website, <https://merlinmelanomatest.com/us/our-publications/>

## Billing and Coverage:

The Merlin test is 100% covered by Medicare. Regardless of your patients' insurance coverage, SkylineDx has a dedicated billing team who can provide detailed information and support on coverage, claims and appeals, and payment plans.

For complete information about the Merlin test, please visit our website at:

[MerlinMelanomaTest.com](https://MerlinMelanomaTest.com)